BSX Stock Analysis: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$44.65
-0.12 (-0.27%)
▼
5d:
+0.11%
30d:
-7.63%
90d:
-27.74%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 29, 2026
14d
Smart Money Accumulation
None View Scanner →
Strength: 8.0/10
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
8 traders called BSX this week
82% bullish • 2 bearish
82% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BSX appears deeply undervalued. Market expects -14.2% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: BSX appears deeply undervalued. Market expects -14.2% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$99.70
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$61.90
27.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $44.65, which is considered slightly low relative to its 30-day fair value range of $43.87 to $47.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.0) compared to its historical average (19.0). Remarkably, the market is currently pricing in an annual earnings decline of 14.2% over the next few years. This pessimistic expectation contrasts with the company's recent 100% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a strong downtrend. Immediate support is located at $42.25, while resistance sits at $46.37.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $73.86 (+65.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BSX is in a strong downtrend. Immediate support is located at $42.25, while resistance sits at $46.37.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $73.86 (+65.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$43.87 -
$47.49
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 65.4% below Wall St target ($73.86)
Trading Range Analysis
30-Day Trading Range
$43.87 -
$47.49
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$42.25
Resistance Level
$46.37
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.03
Wall Street Target
$73.86
(+65.4%)
Revenue Growth (YoY)
11.6%
Earnings Growth (YoY)
100.0%
Profit Margin
17.3%
Valuation Discount vs History
-14.2% cheaper
PE vs Historical
12.0 vs 19.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.2%
(market-implied from PE analysis)
1-Year Target
$40.19
(-10%)
2-Year Target
$36.17
(-19%)
3-Year Target
$32.55
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→19)
$51.40
(+15%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 10.4%)
$108.89
(+144%)
Base:
(SPY PE: 12.0, Growth: 10.4%)
$60.16
(+35%)
Bear:
(PE: 10.2, Growth: 10.4%)
$51.13
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 18.73 | Current EPS (TTM): $2.39
Bull Case
$76.46
(+71%)
Analyst growth 55.3%, PE expands to 20.6
Base Case
$69.51
(+56%)
Market implied 55.3%, PE stable at 18.7
Bear Case
$30.44
(-32%)
Severe decline -20.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.0 to 19.0
Stabilization Target:
$70.50
(+57.9%)
PE Expansion Potential:
+57.9%
Share & Embed Analysis
Last updated: July 14, 2026 4:42 AM ET
Data refreshes hourly during market hours. Next update: 5:42 AM
Data refreshes hourly during market hours. Next update: 5:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
5
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-30
Ro Khanna
SELL
2026-03-23
Ro Khanna
SELL
2026-02-24
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 67 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 57 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 62 BUY |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
